Blog Category

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in A...

July 2nd, 2020

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cance...

June 10th, 2020

Helsinn announces launch of oral formulation of Akynzeo® in China

June 9th, 2020

Helsinn announces FDA acceptance of IND application for TAS0953/HM06 in Patients...

June 8th, 2020

Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fo...

June 2nd, 2020

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Eva...

May 13th, 2020

Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VAL...

April 20th, 2020

Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupi...

March 23rd, 2020

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress...

February 14th, 2020

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn C...

January 31st, 2020

Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company o...

January 27th, 2020

Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® (ALOXI®) in Russia and CIS reg...

Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn...

January 14th, 2020

The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of canc...

Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors

January 13th, 2020